MK-0429

MK-0429

M655254-1ml

1ml

10mM in DMSO

-80℃储存

超低温冰袋运输

MK-0429 (L-000845704) is an orally active, potent, selective and nonpeptide pan-integrin antagonist with IC 50 values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for αvβ1 , αvβ3 , αvβ5 , αvβ6 , αvβ8 and α5β1 , respectively . In Vivo MK-0429 (100 or 300 mg/kg, p.o., twice daily b.i.d., 2 weeks) reduces metastatic tumor colony formation and area in the lungs. MK-0429 is safe and efficacious in significantly decreasing melanoma metastasis in the lungs . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: B6D2F1 hybrid female miceDosage: 100 or 300 mg/kg Administration: P.o., twice daily (b.i.d.), 2 weeks Result: MK-0429 at 100 and 300 mg/kg reduced the number of metastatic tumor colonies by 64 and 57%, respectively, and the high dose also reduced the tumor area by 60% as compared to the vehicle.

MK-0429 (L-000845704) 是一种口服活性、强效、选择性和非肽类泛整合素拮抗剂，对 αvβ1 、αvβ3 、αvβ5 、αvβ6 、αvβ8 和 α5β1 的 IC 50 值分别为 1.6 nM、2.8 nM、0.1 nM、0.7 nM、0.5 nM 和 12.2 nM。

227963-15-7(DMSO)

C23H29N5O4

439.51 g/mol

COC1=NC=C(C=C1)C(CC(=O)O)N2CCN(C2=O)CCCC3=NC4=C(CCCN4)C=C3